Greater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival

Abstract To evaluate tumor blood flow using 15O-water positron emission tomography (PET) in patients with non-small cell lung cancer (NSCLC) before and after chemotherapy with bevacizumab, and to investigate the effects of bevacizumab on tumor blood flow changes and progression-free survival (PFS)....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daisuke Katayama, Masahiro Yanagawa, Keiko Matsunaga, Hiroshi Watabe, Tadashi Watabe, Hiroki Kato, Takashi Kijima, Yoshito Takeda, Atsushi Kumanogoh, Eku Shimosegawa, Jun Hatazawa, Noriyuki Tomiyama
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/86d8996d644e4fe19bb0c89ae9811f40
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:86d8996d644e4fe19bb0c89ae9811f40
record_format	dspace
spelling	oai:doaj.org-article:86d8996d644e4fe19bb0c89ae9811f402021-12-02T13:24:14ZGreater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival10.1038/s41598-021-86405-w2045-2322https://doaj.org/article/86d8996d644e4fe19bb0c89ae9811f402021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86405-whttps://doaj.org/toc/2045-2322Abstract To evaluate tumor blood flow using 15O-water positron emission tomography (PET) in patients with non-small cell lung cancer (NSCLC) before and after chemotherapy with bevacizumab, and to investigate the effects of bevacizumab on tumor blood flow changes and progression-free survival (PFS). Twelve patients with NSCLC were enrolled. Six patients underwent chemotherapy with bevacizumab and the other six without bevacizumab. 15O-water dynamic PET scans were performed within 1 week before the start of chemotherapy and within 1 week after the first day of chemotherapy. Tumor blood flow was analyzed quantitatively using a single one-tissue compartment model with the correction of pulmonary circulation blood volume and arterial blood volume via an image-derived input function. In the bevacizumab group, mean tumor blood flow was statistically significantly reduced post-chemotherapy (pre-chemotherapy 0.27 ± 0.14 mL/cm3/min, post-chemotherapy 0.18 ± 0.12 mL/cm3/min). In the no bevacizumab group, there was no significant difference between mean tumor perfusion pre-chemotherapy (0.42 ± 0.42 mL/cm3/min) and post-chemotherapy (0.40 ± 0.27 mL/cm3/min). In the bevacizumab group, there was a positive correlation between the blood flow ratio (tumor blood flow post-chemotherapy/tumor blood flow pre-chemotherapy) and PFS (correlation coefficient 0.94). Mean tumor blood flow decreases after bevacizumab administration and was positively correlated with longer PFS.Daisuke KatayamaMasahiro YanagawaKeiko MatsunagaHiroshi WatabeTadashi WatabeHiroki KatoTakashi KijimaYoshito TakedaAtsushi KumanogohEku ShimosegawaJun HatazawaNoriyuki TomiyamaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Daisuke Katayama Masahiro Yanagawa Keiko Matsunaga Hiroshi Watabe Tadashi Watabe Hiroki Kato Takashi Kijima Yoshito Takeda Atsushi Kumanogoh Eku Shimosegawa Jun Hatazawa Noriyuki Tomiyama Greater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival
description	Abstract To evaluate tumor blood flow using 15O-water positron emission tomography (PET) in patients with non-small cell lung cancer (NSCLC) before and after chemotherapy with bevacizumab, and to investigate the effects of bevacizumab on tumor blood flow changes and progression-free survival (PFS). Twelve patients with NSCLC were enrolled. Six patients underwent chemotherapy with bevacizumab and the other six without bevacizumab. 15O-water dynamic PET scans were performed within 1 week before the start of chemotherapy and within 1 week after the first day of chemotherapy. Tumor blood flow was analyzed quantitatively using a single one-tissue compartment model with the correction of pulmonary circulation blood volume and arterial blood volume via an image-derived input function. In the bevacizumab group, mean tumor blood flow was statistically significantly reduced post-chemotherapy (pre-chemotherapy 0.27 ± 0.14 mL/cm3/min, post-chemotherapy 0.18 ± 0.12 mL/cm3/min). In the no bevacizumab group, there was no significant difference between mean tumor perfusion pre-chemotherapy (0.42 ± 0.42 mL/cm3/min) and post-chemotherapy (0.40 ± 0.27 mL/cm3/min). In the bevacizumab group, there was a positive correlation between the blood flow ratio (tumor blood flow post-chemotherapy/tumor blood flow pre-chemotherapy) and PFS (correlation coefficient 0.94). Mean tumor blood flow decreases after bevacizumab administration and was positively correlated with longer PFS.
format	article
author	Daisuke Katayama Masahiro Yanagawa Keiko Matsunaga Hiroshi Watabe Tadashi Watabe Hiroki Kato Takashi Kijima Yoshito Takeda Atsushi Kumanogoh Eku Shimosegawa Jun Hatazawa Noriyuki Tomiyama
author_facet	Daisuke Katayama Masahiro Yanagawa Keiko Matsunaga Hiroshi Watabe Tadashi Watabe Hiroki Kato Takashi Kijima Yoshito Takeda Atsushi Kumanogoh Eku Shimosegawa Jun Hatazawa Noriyuki Tomiyama
author_sort	Daisuke Katayama
title	Greater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival
title_short	Greater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival
title_full	Greater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival
title_fullStr	Greater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival
title_full_unstemmed	Greater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival
title_sort	greater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/86d8996d644e4fe19bb0c89ae9811f40
work_keys_str_mv	AT daisukekatayama greaterreductionsinbloodflowafterantiangiogenictreatmentinnonsmallcelllungcancerpatientsareassociatedwithshorterprogressionfreesurvival AT masahiroyanagawa greaterreductionsinbloodflowafterantiangiogenictreatmentinnonsmallcelllungcancerpatientsareassociatedwithshorterprogressionfreesurvival AT keikomatsunaga greaterreductionsinbloodflowafterantiangiogenictreatmentinnonsmallcelllungcancerpatientsareassociatedwithshorterprogressionfreesurvival AT hiroshiwatabe greaterreductionsinbloodflowafterantiangiogenictreatmentinnonsmallcelllungcancerpatientsareassociatedwithshorterprogressionfreesurvival AT tadashiwatabe greaterreductionsinbloodflowafterantiangiogenictreatmentinnonsmallcelllungcancerpatientsareassociatedwithshorterprogressionfreesurvival AT hirokikato greaterreductionsinbloodflowafterantiangiogenictreatmentinnonsmallcelllungcancerpatientsareassociatedwithshorterprogressionfreesurvival AT takashikijima greaterreductionsinbloodflowafterantiangiogenictreatmentinnonsmallcelllungcancerpatientsareassociatedwithshorterprogressionfreesurvival AT yoshitotakeda greaterreductionsinbloodflowafterantiangiogenictreatmentinnonsmallcelllungcancerpatientsareassociatedwithshorterprogressionfreesurvival AT atsushikumanogoh greaterreductionsinbloodflowafterantiangiogenictreatmentinnonsmallcelllungcancerpatientsareassociatedwithshorterprogressionfreesurvival AT ekushimosegawa greaterreductionsinbloodflowafterantiangiogenictreatmentinnonsmallcelllungcancerpatientsareassociatedwithshorterprogressionfreesurvival AT junhatazawa greaterreductionsinbloodflowafterantiangiogenictreatmentinnonsmallcelllungcancerpatientsareassociatedwithshorterprogressionfreesurvival AT noriyukitomiyama greaterreductionsinbloodflowafterantiangiogenictreatmentinnonsmallcelllungcancerpatientsareassociatedwithshorterprogressionfreesurvival
_version_	1718393106281267200

Greater reductions in blood flow after anti-angiogenic treatment in non-small cell lung cancer patients are associated with shorter progression-free survival

Ejemplares similares